Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Metcalfe, A. Poll, R. Royer, Sonia Nanda, M. Llacuachaqui, Ping Sun, S. Narod, S. Narod (2013)
A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testingBritish Journal of Cancer, 109
K. Metcalfe, N. Mian, Melissa Enmore, A. Poll, M. Llacuachaqui, Sonia Nanda, P. Sun, K. Hughes, S. Narod (2012)
Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screeningBreast Cancer Research and Treatment, 133
A. Finch, J. Lubiński, P. Møller, C. Singer, B. Karlan, L. Senter, B. Rosen, L. Maehle, P. Ghadirian, C. Cybulski, T. Huzarski, A. Eisen, W. Foulkes, C. Kim-sing, P. Ainsworth, N. Tung, H. Lynch, S. Neuhausen, K. Metcalfe, I. Thompson, Joan Murphy, P. Sun, S. Narod (2014)
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 15
K. Metcalfe, H. Lynch, W. Foulkes, N. Tung, C. Kim-sing, O. Olopade, A. Eisen, B. Rosen, C. Snyder, Shelley Gershman, P. Sun, S. Narod (2015)
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.JAMA oncology, 1 3
J Armstrong, M Toscano, N Kotchko
Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study [published online October 1, 2015].
K. Metcalfe, Shelley Gershman, P. Ghadirian, H. Lynch, C. Snyder, N. Tung, C. Kim-sing, A. Eisen, W. Foulkes, B. Rosen, P. Sun, S. Narod (2014)
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysisThe BMJ, 348
J. Gronwald, T. Huzarski, T. Byrski, T. Dębniak, K. Metcalfe, S. Narod, J. Lubiński (2006)
Direct-to-patient BRCA1 testing: the Twoj Styl experienceBreast Cancer Research and Treatment, 100
Opinion EDITORIAL Genetic Testing for BRCA Mutations Today and Tomorrow— About the ABOUT Study Steven Narod, MD In the United States, it is widely recommended that women transfer (eg, print or electronic media) need to be explored. who get genetic testing for BRCA1 or BRCA2 mutations see a If testing panels expand beyond BRCA1 and BRCA2 to genetic counselor before being tested. Despite this recommen- include 20 or more genes, or if genes for multiple diseases dation, only 38% of women who were offered genetic testing are combined into a single test, it will be daunting to cover in 2012 through 1 large com- all possible outcomes with a pretest counseling process. mercial health insurance Another important consideration is the need for rapid return Related article page 1251 group saw a geneticist or ge- of genetic information at the time of a new cancer diagnosis, netic counselor before being because mutation status can be very helpful for making 1 2,3 offered or refused genetic testing. Armstrong and colleagues decisions about therapies. report that women who saw a genetics health professional be- It is not surprising that the principal outcomes of inter- fore testing benefited from the interaction in terms
JAMA Oncology – American Medical Association
Published: Dec 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.